Compare Figs Inc (FIGS) vs Summit Therapeutics Inc (SMMT) Price & Performance

FIGS stock trades at $14.50, up 0.76% today, with strong technical momentum and bullish moving averages. Recent Q2 2026 earnings beat expectations with $0.11 EPS and 29% revenue growth, leading to a raised 2026 outlook. The company maintains a high gross margin of 68.91% but faces valuation concerns with a P/E of 43.24. Analyst sentiment is positive with a $19.50 consensus price target.

Outlook remains favorable due to accelerating revenue growth and margin expansion, though the rich valuation and execution risks in H2 2026 pose challenges. Institutional buying and a $100 million share buyback program support bullish sentiment, but investors should weigh premium multiples against growth sustainability.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.